Felley Christian, Mottet Christian, Hess Jurg, Juillerat Pascal, Guyot Jean, Delarive Joakim, Michetti Pierre
Service de gastro-entérologie et hépatologie, CHUV, 1011 Lausanne.
Rev Med Suisse. 2007 Jan 24;3(95):201-2, 204-6, 208-14.
There was no real therapeutic advances in inflammatory bowel diseases last year. In addition to infliximab, new anti-TNF-alpha agents will soon become available.